PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Trastuzumab is the only HER2/neu-directed therapy to have received Food and Drug Administration approval for the treatment of patients with metastatic breast cancer. The efficacy of trastuzumab depends on the HER2/neu status of the tumour and the patient's prior treatment, but even when patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fujita, T, Doihara, H, Kawasaki, K, Takabatake, D, Takahashi, H, Washio, K, Tsukuda, K, Ogasawara, Y, Shimizu, N
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2006
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361109/
https://ncbi.nlm.nih.gov/pubmed/16404430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602926
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados